Erratum
for
Coudert et al., J Clin Oncol 25 (19) 2678-2684.
Journal of Clinical Oncology, Vol 25, No 31 (November 1), 2007: pp. 5048
© 2007 American Society of Clinical Oncology.
DOI: 10.1200/JCO.2007.14.4345
ERRATA
The July 1, 2007, article by Coudert et al, entitled "Multicenter Phase II Trial of Neoadjuvant Therapy With Trastuzumab, Docetaxel, and Carboplatin for Human Epidermal Growth Factor Receptor-2–Overexpressing Stage II or III Breast Cancer: Results of the GETN(A)-1 Trial" (J Clin Oncol 25:2678-2684, 2007) contained errors.
In Table 4, the results of the study by Mehta et al were incorrectly given. Under Treatment Protocol, a weekly dosage of docetaxel at 80 mg/m2 was listed, whereas it should have shown a weekly dosage of paclitaxel at 80 mg/m2. Also, dose-dense AC was listed as being given every 3 weeks, whereas it should have read "dose-dense AC/2 weeks." In addition to the current data, the following should have been listed as a separate row for the 2005 study by Mehta et al: No. = 16, OR = NR, cCR = NR, pCR = 75.
In the References section, the citation for the Mehta study was erroneously given (ref. no. 48), and should have read:
Mehta RS, Schubbert T, Hsiang D, et al: High pathological complete remission rates with paclitaxel and carboplatin ± trastuzumab (TC±H) following dose dense doxorubicin and cyclophosphamide (AC) supported by GM-CSF in breast cancer-a phase II study. Breast Cancer Res Treat 89, 2005 (suppl 1, abst 5056)
The online version has been corrected in departure from the print.

CiteULike Complore Connotea Del.icio.us Digg Facebook Reddit Technorati Twitter What's this?
|